DaVita Inc. found using ticker (DVA) have now 8 analysts covering the stock with the consensus suggesting a rating of ‘Hold’. The range between the high target price and low target price is between 150 and 112 with a mean TP of 126. With the stocks previous close at 115.29 this now indicates there is a potential upside of 9.3%. The 50 day MA is 106.73 and the 200 day moving average is 116.93. The company has a market cap of $11,853m. Find out more information at: https://www.davita.com
The potential market cap would be $12,954m based on the market concensus.
DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure or end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also provides outpatient, hospital inpatient, and home-based hemodialysis services; owns clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers. In addition, the company provides disease management services; vascular access services; clinical research programs; physician services; and comprehensive care services. As of December 31, 2020, it provided dialysis and administrative services in the United States through a network of 2,816 outpatient dialysis centers serving approximately 204,200 patients; and operated 321 outpatient dialysis centers located in 10 countries outside of the United States serving approximately 36,700 patients. Further, the company provides acute inpatient dialysis services in approximately 900 hospitals and related laboratory services in the United States. The company was formerly known as DaVita HealthCare Partners Inc. and changed its name to DaVita Inc. in September 2016. DaVita Inc. was incorporated in 1994 and is headquartered in Denver, Colorado.
